modelAminolevulinicAcid

Diagram of AminolevulinicAcid

Extends from Pharmacolibrary.Drugs.ATC.L.L01XD04.

Information

name:AminolevulinicAcid
ATC code:L01XD04
route:oral
compartments:1
dosage:20mg
volume of distribution:0.39L
clearance:0.13L/h/kg
other parameters in model implementation

Aminolevulinic acid (ALA) is a natural precursor in the heme biosynthesis pathway and is used as a photosensitizing agent in photodynamic therapy, particularly for the treatment of actinic keratosis, superficial basal cell carcinoma, and as an adjunct in tumor imaging. It is approved for topical and oral use in some countries but its use as an anticancer agent is under continued investigation.

Pharmacokinetics

Pharmacokinetic parameters for orally administered aminolevulinic acid in healthy adult volunteers.

References

  1. Bernal García, LM, et al., & López Macías, M (2015). Fluorescence-guided resection with 5-aminolevulinic acid of meningeal sarcoma in a child. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 31(7) 1177–1180. DOI:10.1007/s00381-015-2703-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25863951

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)